Literature DB >> 23276707

A novel homozygous GALC mutation: very early onset and rapidly progressive Krabbe disease.

Fatih Kardas1, Asli Subasioglu Uzak, Mohammad Arif Hossain, Norio Sakai, Mehmet Canpolat, Ali Yıkılmaz.   

Abstract

A clear cut genotype-phenotype correlation for Krabbe disease is not available. Therefore, it is important to identify new mutations and their associated phenotypes to predict the prognosis of the disease. The aim of this study is to identify the causative mutation(s) in a family with Krabbe disease. After a clinical evaluation and suspicion of Krabbe disease galactocerebrosidase activity was analyzed and GALC gene mutation analysis was performed. The galactocerebrosidase enzyme activity was 0.01 nmol/mg/h protein (normal range 0.8-4). For further investigation mutation screening was performed by Sanger sequencing across the 17 exons of GALC gene. A novel homozygous mutation c.727delT (p.S243QfsX7) was found. In this study we present the clinical findings along with a novel GALC mutation in a consanguineous Turkish family. Although the relationship between the various genotypes and phenotypes in Krabbe disease has not been fully elucidated an accurate genetic family study is helpful for genetic counseling follow-up and therapy of Krabbe disease. Also, it is important to identify new mutations in order to clarify their clinical importance, to assess the prognosis of the disease, and to suggest either prenatal diagnosis or preimplantation genetic diagnosis to the effected families.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23276707     DOI: 10.1016/j.gene.2012.12.040

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  Mutations in GALC cause late-onset Krabbe disease with predominant cerebellar ataxia.

Authors:  Yi-Hong Shao; Karine Choquet; Roberta La Piana; Martine Tétreault; Marie-Josée Dicaire; Kym M Boycott; Jacek Majewski; Bernard Brais
Journal:  Neurogenetics       Date:  2016-02-26       Impact factor: 2.660

Review 2.  Krabbe Disease in the Arab World.

Authors:  Hatem Zayed
Journal:  J Pediatr Genet       Date:  2015-03

3.  DNA promoter hypermethylation contributes to down-regulation of galactocerebrosidase gene in lung and head and neck cancers.

Authors:  Jiangzhou Peng; Baishen Chen; Zhuojian Shen; Heran Deng; Degang Liu; Xuan Xie; Xiangfeng Gan; Xia Xu; Zhiquan Huang; Ju Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  A novel homozygous GALC variant has been associated with Krabbe disease in a consanguineous family.

Authors:  Feyza Nur Tuncer; Sibel Aylin Ugur Iseri; Zuhal Yapici; Mahmut Demir; Meryem Karaca; Mustafa Calik
Journal:  Neurol Sci       Date:  2018-09-12       Impact factor: 3.307

5.  Neuroradiological, neurophysiological and molecular findings in infantile Krabbe disease: two case reports.

Authors:  E Vargiami; E Papathanasiou; S Batzios; M Kyriazi; E Dimitriou; A Anastasiou; H Michelakakis; A-K Giese; D I Zafeiriou
Journal:  Balkan J Med Genet       Date:  2016-08-02       Impact factor: 0.519

6.  GALC mutations in Chinese patients with late-onset Krabbe disease: a case report.

Authors:  Shunzhi Zhuang; Lingen Kong; Caiming Li; Likun Chen; Tingting Zhang
Journal:  BMC Neurol       Date:  2019-06-11       Impact factor: 2.474

7.  Genome-Wide Association Study of Staphylococcus aureus Carriage in a Community-Based Sample of Mexican-Americans in Starr County, Texas.

Authors:  Eric L Brown; Jennifer E Below; Rebecca S B Fischer; Heather T Essigmann; Hao Hu; Chad Huff; D Ashley Robinson; Lauren E Petty; David Aguilar; Graeme I Bell; Craig L Hanis
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

8.  Clinical and molecular report of novel GALC mutations in Moroccan patient with Krabbe disease: case report.

Authors:  M Zerkaoui; I Ratbi; B Castellotti; C Gellera; J Lyahyai; Y Kriouile; A Sefiani
Journal:  BMC Pediatr       Date:  2015-11-13       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.